Literature DB >> 28299176

Predicting survival time for metastatic castration resistant prostate cancer: An iterative imputation approach.

Detian Deng1, Yu Du1, Zhicheng Ji1, Karthik Rao2, Zhenke Wu1, Yuxin Zhu1, R Yates Coley1.   

Abstract

In this paper, we present our winning method for survival time prediction in the 2015 Prostate Cancer DREAM Challenge, a recent crowdsourced competition focused on risk and survival time predictions for patients with metastatic castration-resistant prostate cancer (mCRPC). We are interested in using a patient's covariates to predict his or her time until death after initiating standard therapy. We propose an iterative algorithm to multiply impute right-censored survival times and use ensemble learning methods to characterize the dependence of these imputed survival times on possibly many covariates. We show that by iterating over imputation and ensemble learning steps, we guide imputation with patient covariates and, subsequently, optimize the accuracy of survival time prediction. This method is generally applicable to time-to-event prediction problems in the presence of right-censoring. We demonstrate the proposed method's performance with training and validation results from the DREAM Challenge and compare its accuracy with existing methods.

Entities:  

Keywords:  Ensemble learning; Iterative imputation; Survival Time Prediction; multiple imputation

Year:  2016        PMID: 28299176      PMCID: PMC5321124          DOI: 10.12688/f1000research.8628.1

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  15 in total

1.  Non-linear survival analysis using neural networks.

Authors:  Ruth M Ripley; Adrian L Harris; Lionel Tarassenko
Journal:  Stat Med       Date:  2004-03-15       Impact factor: 2.373

2.  Survival model predictive accuracy and ROC curves.

Authors:  Patrick J Heagerty; Yingye Zheng
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

3.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

4.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Authors:  Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

5.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Authors:  Howard I Scher; Xiaoyu Jia; Kim Chi; Ronald de Wit; William R Berry; Peter Albers; Brian Henick; David Waterhouse; Dean J Ruether; Peter J Rosen; Anthony A Meluch; Luke T Nordquist; Peter M Venner; Axel Heidenreich; Luis Chu; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

6.  Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Daniel P Petrylak; Nicholas J Vogelzang; Nikolay Budnik; Pawel Jan Wiechno; Cora N Sternberg; Kevin Doner; Joaquim Bellmunt; John M Burke; Maria Ochoa de Olza; Ananya Choudhury; Juergen E Gschwend; Evgeny Kopyltsov; Aude Flechon; Nicolas Van As; Nadine Houede; Debora Barton; Abderrahim Fandi; Ulf Jungnelius; Shaoyi Li; Ronald de Wit; Karim Fizazi
Journal:  Lancet Oncol       Date:  2015-03-03       Impact factor: 41.316

7.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors:  Ian F Tannock; Karim Fizazi; Sergey Ivanov; Camilla Thellenberg Karlsson; Aude Fléchon; Iwona Skoneczna; Francisco Orlandi; Gwenaelle Gravis; Vsevolod Matveev; Sevil Bavbek; Thierry Gil; Luciano Viana; Osvaldo Arén; Oleg Karyakin; Tony Elliott; Alison Birtle; Emmanuelle Magherini; Laurence Hatteville; Daniel Petrylak; Bertrand Tombal; Mark Rosenthal
Journal:  Lancet Oncol       Date:  2013-06-04       Impact factor: 41.316

8.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Authors:  Karim Fizazi; Karim S Fizazi; Celestia S Higano; Joel B Nelson; Martin Gleave; Kurt Miller; Thomas Morris; Faith E Nathan; Stuart McIntosh; Kristine Pemberton; Judd W Moul
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

9.  Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models.

Authors:  Harald Binder; Martin Schumacher
Journal:  BMC Bioinformatics       Date:  2008-01-10       Impact factor: 3.169

10.  A gradient boosting algorithm for survival analysis via direct optimization of concordance index.

Authors:  Yifei Chen; Zhenyu Jia; Dan Mercola; Xiaohui Xie
Journal:  Comput Math Methods Med       Date:  2013-11-20       Impact factor: 2.238

View more
  1 in total

1.  Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review.

Authors:  M Pinart; F Kunath; V Lieb; I Tsaur; B Wullich; Stefanie Schmidt
Journal:  World J Urol       Date:  2018-12-15       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.